News
Check out the posts below to learn the latest updates on our progress
- April 3 2019Same Day Transduction and In Vivo Expansion of a Chimeric Antigen Receptor with a Synthetic Driver Construct for Adoptive Cellular Therapy
AACR 2019 - April 3 2019A High-Throughput Screening Strategy for the Identification of Novel Lymphoproliferative Elements
AACR 2019 - April 3 2019CAB-CAR-T: The Prioritization of Cell Surface Protein Targets for Conditionally Active Biologics to Treat All Solid Tumors
AACR 2019 - April 3 2019A Novel Conditionally Active Biologics Approach to Minimize On-target Off-tumor Effects in Adoptive Immunotherapy
AACR 2019 - March 31 2019F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies
Business Wire - March 29 2019Taking the Next Step: What We’ve Learned About CAR-T So Far, and What It Means Going Forward
- January 6 2019Cancer Doesn’t See Borders – And Neither Should Biotech
- November 13 2018F1 Oncology’s International Affiliate, EXUMA Biotechnology, Announces Acquisition of Strategic CAR-T Assets
- November 13 2018F1 ONCOLOGY’S INTERNATIONAL AFFILIATE, EXUMA BIOTECHNOLOGY, ANNOUNCES ACQUISITION OF STRATEGIC CAR-T ASSETSPRNewswire
- September 14 2018Keynote Announcement: BioFlorida Conference 2018
